There are two legal ways to get retatrutide. You probably qualify for neither.

The short answer: in the US, there are two legal ways to get retatrutide. Join a clinical trial, or get into Eli Lilly's expanded access program through your doctor. That's it.

No pharmacy can legally compound it. No doctor can write you a normal prescription for it, because there's no approved product to fill. Every vial sold online, at a med spa or through a "wellness" clinic is an unapproved drug, whatever the label says.

Here's each route, what the paperwork actually says, and where the line is.

Status as of October 21, 2026: retatrutide is not approved by FDA or any other regulator. Lilly plans to file in Q1 2027. Lilly has filed eleven lawsuits against sellers since August. This is not legal or medical advice.

It's legal to be given retatrutide inside a Lilly trial or under Lilly's expanded access program. It's not legal for anyone to sell it to you.

Lilly put it plainly in August: "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world. It cannot be sold to consumers" (Lilly, Aug 12, 2026). Lilly plans to submit it to FDA in the first quarter of 2027 (Lilly, July 23, 2026). Approval, if it comes, would follow FDA's review after that.

You search ClinicalTrials.gov, find a trial that's enrolling, and see if you fit its criteria. Right now that's a short list.

ClinicalTrials.gov lists 34 studies that mention retatrutide. When I filtered for ones still recruiting on October 21, only one Lilly retatrutide trial had US sites: a phase 3 study in people with fatty liver disease (MASLD) at higher risk of serious liver problems, comparing tirzepatide, retatrutide and placebo, with about 4,500 participants planned across 34 countries (ClinicalTrials.gov, NCT07165028). It's not a weight-loss trial you can walk into because you want to lose weight.

None of the big TRIUMPH obesity trials is listed as recruiting. They also kept out anyone who'd taken weight-loss drugs in the 90 days before screening, which matters if you're on tirzepatide now. More on that in switching from tirzepatide to retatrutide.

In a trial you might get placebo. That's the deal.

Yes. It exists, it's free, and it's built for a small group of very sick patients. Your doctor has to apply, not you.

The program is registered as "Pre-approval Expanded Access of Retatrutide," first posted in June (ClinicalTrials.gov, NCT07629401). To qualify, per Lilly (Lilly Medical, reviewed Aug 26, 2026), you need all of these:

The paperwork falls on the physician. Lilly says the doctor calls the Lilly Answers Center, fills out an intake form, signs an agreement, applies to the regulator as the sponsor, gets an ethics board (IRB) approval and handles safety reporting. Lilly doesn't ship to patients. It provides the drug at no cost, and the program ends once retatrutide is approved and on the market.

Lilly also says availability depends on geography and supply. So meeting the criteria doesn't guarantee a yes.

Not in the normal sense. A prescription is for an approved drug a pharmacy can fill. There isn't one.

The only way a doctor can legally put retatrutide in you outside a trial is the expanded access route above. FDA lists "Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers" among the companies it has warned (FDA, updated Oct 1, 2026). If an online clinic is offering you a retatrutide "prescription" with a quick intake form, that's the thing FDA is warning about.

No. FDA's own words: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition" (FDA, updated Oct 1, 2026).

The legal reason is in how compounding law handles raw ingredients. FDA spelled it out in a warning letter to a retatrutide seller (FDA, Sept 9, 2025):

The shortage loophole that let pharmacies copy semaglutide and tirzepatide doesn't apply here either. A shortage needs an approved drug to run short of. There is no approved retatrutide.

FDA also lists warnings to ingredient distributors "for selling retatrutide and other GLP-1 drugs to compounders" and to outsourcing facilities "for repackaging retatrutide." So "compounded retatrutide" is a contradiction. Whatever a pharmacy is selling under that name, it isn't a lawful compounded drug. Where every other peptide stands is on the compounding status tracker.

The label doesn't make it legal to sell for human use. FDA looks at how it's marketed, not the sticker.

FDA says it has warned companies that "illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption,'" and that these products "have been sold directly to consumers for human use with dosing instructions" (FDA). In a March letter to one retatrutide seller, FDA said that despite the research-use label, "evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA, March 31, 2026).

What does that mean for you as the buyer? Every enforcement action I found targets sellers, not buyers. That's not the same as buying it being legal, and it says nothing about what's in the vial. I went through the label question in more depth in what RUO actually means and in FDA's letters to five peptide vendors.

And the vial is the real problem. CBS News reported this month that FDA received reports of two deaths in people who took products claiming to be retatrutide, though the details aren't verified and it's unclear whether the drug was to blame. The same story says America's Poison Centers logged 862 retatrutide exposures in the three months ending in September, up from 249 in the first three months of 2026 (CBS News, Oct 13, 2026).

Eleven lawsuits since August: six filed August 12 and five filed October 8.

The legal theory is worth knowing. None of the October suits tries to enforce federal drug law directly. Against the online sellers, Lilly uses state unfair-competition and consumer-protection laws in eight states. Against the clinic and med spa, it claims false advertising under the federal Lanham Act, over statements about clinical trial support and regulatory status (same source). Lilly also says it has referred more than 200 people and companies to FDA, the Justice Department, state attorneys general and licensing boards.

A Lilly spokesperson told The Washington Post it has settled two of the August cases, including with Texas Peptides, which agreed to stop selling (Becker's, Oct 13, 2026). The rest are allegations, and none has been decided. Case by case: Lilly's retatrutide lawsuits.

Generally, no. FDA says: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use" (FDA).

FDA sometimes looks the other way on small personal imports, but only when a list of conditions is met. Among them: it's for a serious condition where effective treatment "may not be available domestically," there's "no known commercialization or promotion of the product to persons residing in the U.S.," it doesn't pose an unreasonable risk, it's no more than about a three-month supply, and you give the name of the US-licensed doctor treating you with it.

My read: retatrutide fails that test on several counts. It's promoted to Americans everywhere, approved obesity drugs exist here, and FDA's own pages call the products sold to consumers potentially harmful. FDA hasn't said anything specific about personal retatrutide imports that I could find. I wouldn't treat that silence as permission.

No. All three regulators say it's unapproved and shouldn't be bought outside a trial. Lilly's liver-disease trial has sites in all three (ClinicalTrials.gov).

I've written openly about my own first month on retatrutide, so I'm not going to pretend nobody's doing this. But "everyone's doing it" and "it's legal" are different questions, and this post is about the second one.

The legal answer is short. A trial, or expanded access if you're sick enough and your doctor is willing to do the paperwork. Everything else, from the compounding pharmacy to the med spa to the research site, is selling an unapproved drug. FDA has said so in writing, and Lilly has eleven lawsuits saying the same. When Lilly files in 2027, the tracker will show it. What it'll probably cost when it lands is in how much retatrutide costs.

If you've tried to get into a retatrutide trial or the expanded access program, reply and tell me how it went: who you contacted, what they said, and how long it took. Almost nobody has written about what that process looks like from the patient side.